India’s Precision Medicine: A Vision Hindered by Biobank Regulations
Precision medicine, a transformative approach to healthcare, is redefining the landscape of disease diagnosis and treatment. From groundbreaking personalised healthcare solutions to innovations like mRNA vaccines and gene-editing technologies, the field promises a new era in medical science. Yet, as India stands on the cusp of this revolution, a significant hurdle looms: the lack of robust biobank regulations.
Biobanks, essential repositories of biological samples, are critical to the success of precision medicine. These collections of blood, DNA, and tissue samples, coupled with genetic data, form the backbone of research aimed at developing targeted therapies for diseases like cancer and diabetes. However, as highlighted in a recent analysis by The Hindu, India’s inconsistent biobank regulations threaten public trust and impede progress.
The Promise of Precision Medicine
In recent years, precision medicine has witnessed remarkable achievements. Through gene therapy, researchers have restored vision in individuals with genetic mutations, while in the U.K., scientists have reversed diabetes using reengineered stem cells. The rapid development of COVID-19 vaccines using the mRNA platform, which earned a Nobel Prize, further underscores the potential of precision medicine.
India’s Growing Market
The Indian precision medicine market is burgeoning, with projections estimating a value exceeding $5 billion by 2030. Initiatives like the BioE3 policy and the approval of NexCAR19, a domestically developed CAR-T cell therapy, mark significant strides. However, the true potential of these advancements lies in aligning biobank regulations with international standards.
The Biobank Conundrum
While countries like the U.K., U.S., and Japan have comprehensive biobank regulations ensuring data protection and privacy, India’s framework remains fragmented. The absence of a single authority to regulate biobanks and the lack of penalties for misconduct create risks of ethical violations and undermine public confidence. As the ICMR guidelines illustrate, participants often consent to provide samples without clarity on data usage, raising concerns about privacy and potential discrimination.
A Path Forward
To harness the full potential of precision medicine, India must establish stringent biobank regulations. Aligning with global standards will not only bolster public trust but also position India as a leader in next-generation therapeutics. As part of international groups like the Quad and BRICS, India has the opportunity to expand its pharmaceutical leadership and enhance its soft diplomatic efforts.
Manjeera Gowravaram, a PhD in RNA biochemistry, provides insightful analysis on the intersection of science and policy.
More Articles
Getting licensed or staying ahead in your career can be a journey—but it doesn’t have to be overwhelming. Grab your favorite coffee or tea, take a moment to relax, and browse through our articles. Whether you’re just starting out or renewing your expertise, we’ve got tips, insights, and advice to keep you moving forward. Here’s to your success—one sip and one step at a time!
Nevada has enacted a first‑in‑the‑nation law permitting insurers to sell homeowners policies that exclude wildfire coverage, a move supporters say could help stabilize premiums but critics warn may leave homeowners financially devastated. The policy shift positions Nevada as a testing ground for potential nationwide changes, raising major implications for real estate, mortgage, and insurance professionals as lenders, high‑risk communities, and regulators navigate the evolving landscape.
Tampa Bay’s office sector just delivered its most powerful year in nearly a decade, according to JLL’s Q4 2025 report. With more than 600,000 square feet of positive net absorption, falling vacancies, shrinking inventory, and major tenants like Fisher Investments and GEICO locking in massive leases, the region is emerging as one of the nation’s strongest post‑recovery office markets. The surge in demand for high‑quality space is driving rents up, tightening supply, and setting the stage for continued momentum into 2026.
The Consumer Financial Protection Bureau has proposed new updates to the Nationwide Mortgage Licensing System and Registry, expanding data collection, tightening verification standards, and refreshing record‑retention rules. These changes aim to strengthen background checks, enhance regulatory oversight, and align the system with federal requirements—impacting both current and aspiring mortgage loan originators nationwide.
Nevada has become the first state to let insurers sell homeowners policies that exclude wildfire coverage — a dramatic shift that could reshape insurance pricing across the West. Supporters say the move may lower premiums and spark innovation, while critics warn it could leave homeowners exposed to devastating losses. As regulators and insurers nationwide watch closely, the experiment could have major implications for real estate, mortgages, and insurance markets.
After years of soaring premiums and insurer failures, Florida lawmakers are rolling out a new slate of reforms aimed at finally delivering relief to homeowners. From cracking down on profit‑sharing affiliates to unveiling hidden rate factors and rewarding claim‑free residents, these proposals could reshape the state’s insurance landscape — and bring real savings to property owners and real estate professionals alike.
With traditional CRE lending slowing nationwide, C‑PACE financing is surging to all‑time highs — including a record‑setting $465 million loan for a major D.C. redevelopment. Backed by long repayment terms, fixed rates, and tax‑assessment security, C‑PACE is rapidly becoming a preferred tool for funding energy efficiency, resiliency upgrades, and even large‑scale project recapitalizations. Major players like Nuveen Green Capital and Peachtree Group are driving billions in new volume as 40 states adopt the program, signaling a major shift in how commercial real estate projects are financed.
Biobanks, essential repositories of biological samples, are critical to the success of precision medicine. These collections of blood, DNA, and tissue samples, coupled with genetic data, form the backbone of research aimed at developing targeted therapies for diseases like cancer and diabetes. However, as highlighted in a recent 
While countries like the U.K., U.S., and Japan have comprehensive biobank regulations ensuring data protection and privacy, India’s framework remains fragmented. The absence of a single authority to regulate biobanks and the lack of penalties for misconduct create risks of ethical violations and undermine public confidence. As the 
